Katrine T-B G Schjoldager1, Henrik Clausen. 1. Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark. schjoldager@sund.ku.dk
Abstract
BACKGROUND: Posttranslational modifications (PTMs) greatly expand the function and regulation of proteins, and glycosylation is the most abundant and diverse PTM. Of the many different types of protein glycosylation, one is quite unique; GalNAc-type (or mucin-type) O-glycosylation, where biosynthesis is initiated in the Golgi by up to twenty distinct UDP-N-acetyl-α-d-galactosamine:polypeptide N-acetylgalactosaminyltransferases (GalNAc-Ts). These GalNAc-Ts are differentially expressed in cells and have different (although partly overlapping) substrate specificities, which provide for both unique functions and considerable redundancy. Recently we have begun to uncover human diseases associated with deficiencies in GalNAc-T genes (GALNTs). Thus deficiencies in individual GALNTs produce cell and protein specific effects and subtle distinct phenotypes such as hyperphosphatemia with hyperostosis (GALNT3) and dysregulated lipid metabolism (GALNT2). These phenotypes appear to be caused by deficient site-specific O-glycosylation that co-regulates proprotein convertase (PC) processing of FGF23 and ANGPTL3, respectively. SCOPE OF REVIEW: Here we summarize recent progress in uncovering the interplay between human O-glycosylation and protease regulated processing and describes other important functions of site-specific O-glycosylation in health and disease. MAJOR CONCLUSIONS: Site-specific O-glycosylation modifies pro-protein processing and other proteolytic events such as ADAM processing and thus emerges as an important co-regulator of limited proteolytic processing events. GENERAL SIGNIFICANCE: Our appreciation of this function may have been hampered by our sparse knowledge of the O-glycoproteome and in particular sites of O-glycosylation. New strategies for identification of O-glycoproteins have emerged and recently the concept of SimpleCells, i.e. human cell lines made deficient in O-glycan extension by zinc finger nuclease gene targeting, was introduced for broad O-glycoproteome analysis.
BACKGROUND: Posttranslational modifications (PTMs) greatly expand the function and regulation of proteins, and glycosylation is the most abundant and diverse PTM. Of the many different types of protein glycosylation, one is quite unique; GalNAc-type (or mucin-type) O-glycosylation, where biosynthesis is initiated in the Golgi by up to twenty distinct UDP-N-acetyl-α-d-galactosamine:polypeptide N-acetylgalactosaminyltransferases (GalNAc-Ts). These GalNAc-Ts are differentially expressed in cells and have different (although partly overlapping) substrate specificities, which provide for both unique functions and considerable redundancy. Recently we have begun to uncover human diseases associated with deficiencies in GalNAc-T genes (GALNTs). Thus deficiencies in individual GALNTs produce cell and protein specific effects and subtle distinct phenotypes such as hyperphosphatemia with hyperostosis (GALNT3) and dysregulated lipid metabolism (GALNT2). These phenotypes appear to be caused by deficient site-specific O-glycosylation that co-regulates proprotein convertase (PC) processing of FGF23 and ANGPTL3, respectively. SCOPE OF REVIEW: Here we summarize recent progress in uncovering the interplay between human O-glycosylation and protease regulated processing and describes other important functions of site-specific O-glycosylation in health and disease. MAJOR CONCLUSIONS: Site-specific O-glycosylation modifies pro-protein processing and other proteolytic events such as ADAM processing and thus emerges as an important co-regulator of limited proteolytic processing events. GENERAL SIGNIFICANCE: Our appreciation of this function may have been hampered by our sparse knowledge of the O-glycoproteome and in particular sites of O-glycosylation. New strategies for identification of O-glycoproteins have emerged and recently the concept of SimpleCells, i.e. human cell lines made deficient in O-glycan extension by zinc finger nuclease gene targeting, was introduced for broad O-glycoproteome analysis.
Authors: Katrine T Schjoldager; Hiren J Joshi; Yun Kong; Christoffer K Goth; Sarah Louise King; Hans H Wandall; Eric P Bennett; Sergey Y Vakhrushev; Henrik Clausen Journal: EMBO Rep Date: 2015-11-13 Impact factor: 8.807
Authors: Yun Kong; Hiren J Joshi; Katrine Ter-Borch Gram Schjoldager; Thomas Daugbjerg Madsen; Thomas A Gerken; Malene B Vester-Christensen; Hans H Wandall; Eric Paul Bennett; Steven B Levery; Sergey Y Vakhrushev; Henrik Clausen Journal: Glycobiology Date: 2014-08-25 Impact factor: 4.313
Authors: Shengjun Wang; Yang Mao; Yoshiki Narimatsu; Zilu Ye; Weihua Tian; Christoffer K Goth; Erandi Lira-Navarrete; Nis B Pedersen; Asier Benito-Vicente; Cesar Martin; Kepa B Uribe; Ramon Hurtado-Guerrero; Christina Christoffersen; Nabil G Seidah; Rikke Nielsen; Erik I Christensen; Lars Hansen; Eric P Bennett; Sergey Y Vakhrushev; Katrine T Schjoldager; Henrik Clausen Journal: J Biol Chem Date: 2018-03-20 Impact factor: 5.157
Authors: Catharina Steentoft; Sergey Y Vakhrushev; Hiren J Joshi; Yun Kong; Malene B Vester-Christensen; Katrine T-B G Schjoldager; Kirstine Lavrsen; Sally Dabelsteen; Nis B Pedersen; Lara Marcos-Silva; Ramneek Gupta; Eric Paul Bennett; Ulla Mandel; Søren Brunak; Hans H Wandall; Steven B Levery; Henrik Clausen Journal: EMBO J Date: 2013-04-12 Impact factor: 11.598
Authors: Zhang Yang; Adnan Halim; Yoshiki Narimatsu; Hiren Jitendra Joshi; Catharina Steentoft; Katrine Ter-Borch Gram Schjoldager; Morten Alder Schulz; Natalie R Sealover; Kevin J Kayser; Eric Paul Bennett; Steven B Levery; Sergey Y Vakhrushev; Henrik Clausen Journal: Mol Cell Proteomics Date: 2014-08-04 Impact factor: 5.911